![Chris Takimoto](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chris Takimoto
Directeur/Membre du Conseil chez
ALX ONCOLOGY HOLDINGS INC.
Fortune : - $ au 31/05/2026
Profil
Chris H.
Takimoto is currently an Independent Director at ALX Oncology Holdings, Inc. since 2025 and Global Chief Medical Officer at The Start Center For Cancer Research.
Former roles include Chief Medical Officer at IGM Biosciences, Inc. from 2021 to 2024, Senior Vice President-Oncology at Gilead Sciences, Inc. from 2020 to 2021, Chief Medical Officer at Forty Seven LLC from 2016 to 2020, VP-Experimental Medicine Early Development at Janssen Global Services LLC from 2010 to 2016, Senior Director-Translational Medicine at Ortho Biotech Oncology Research & Development from 2008 to 2010, and Associate Professor at the University of Texas Health Science Center At San Antonio.
Education includes undergraduate studies at Stanford University and doctorate degrees from Yale University and Yale School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Chris Takimoto
| Sociétés | Poste | Début |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Directeur/Membre du Conseil | 21/01/2025 |
Anciens postes connus de Chris Takimoto
| Sociétés | Poste | Fin |
|---|---|---|
| IGM BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/10/2024 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/07/2021 |
| FORTY SEVEN, INC. | Directeur Technique/Scientifique/R&D | 01/04/2020 |
Janssen Global Services LLC
 Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Develops treatments for patients in therapeutic areas of healthcare | Corporate Officer/Principal | 01/01/2016 |
Ortho Biotech Oncology Research & Development | Corporate Officer/Principal | 01/01/2010 |
Formation de Chris Takimoto
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Janssen Global Services LLC
Janssen Global Services LLC Pharmaceuticals: MajorHealth Technology Develops treatments for patients in therapeutic areas of healthcare | Health Technology |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Ortho Biotech Oncology Research & Development | |
University of Texas Health Science Center At San Antonio
 University of Texas Health Science Center At San Antonio Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
Choisissez Zonebourse 
